Etanercept, known by the trade name Enbrel, is indicated for reducing the signs and symptoms of Rheumatoid Arthritis. In addition, etanercept, CAS number 185243-69-0, is effective in reduction of symptoms as related to Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Plaque Psoriasis. Developed by researchers at Immunex, etanercept is marketed as Enbrel by Wyeth in North America, and by Takeda Pharmaceuticals in Japan.
Able to inhibit the progression of structural damage with Rheumatoid Arthritis, as well as improve physical function in patients with a moderate to severe case of RA, etanercept is effective in adults and children ages two and older. The recommended dose for patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis is 50 milligrams weekly. Adult patients with Plaque Psoriasis typically receive a 50 milligram dose twice weekly for three months, and then a 50 milligram dose weekly thereafter. Injections of Enbrel, or etanercept, should be administered by a medical professional, and self administration is acceptable only after a patient has received appropriate training in how to prepare and administer the correct dose.
Available as 25 and 50 milligram vials and pre-filled syringes, adverse effects of Enbrel/etanercept are an increased risk of fungal, bacterial and viral infections, diarrhea and rashes. The risk of infections has been clearly stated on the warning labels from the makers of Enbrel, and there have been common reports of patient infections such as tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis. On November 22, 2011, Amgen announced that the patent of the fusion protein that is etanercept, also known as Enbrel, and owned by Hoffman-La Roche Inc. was extended for 17 additional years, due to expire in 2028.
Touted by championship golfer Phil Mickelson, who is also a patient using Enbrel to treat his Psoriatic Arthritis, the benefits of etanercept are considerable. By blocking the actions of a specific chemical in the body, called TNF-alpha, which is known to play a role in inflammation in the body, etanercept proves to not only reduce joint pain and swelling, but it also is efficacious in preventing future joint damage. LGM Pharma provides API Etanercept for research and development purposes, and offers support to clients throughout the entire R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.